Abstract
Aim:
To test the protective effects of betaglucin, a novel beta-glucan, on models of myocardial infarction (MI) in rats and dogs.
Methods:
The left anterior descending (LAD) coronary artery occlusion model was used to induce an MI in rats and dogs. Three doses of betaglucin (10, 30 and 100 mg/kg), propranolol (positive control, 1 mg/kg) and vehicle alone (5% glucose solution) were administered before LAD occlusion, and characteristics of the resulting MI were subsequently assessed. In anesthetized dogs, blood pressure, heart rate, ventricular function, coronary artery blood flow and myocardial oxygen consumption were determined before and after the drug administration.
Results:
The MI mass in both rats and dogs was significantly reduced by betaglucin (30 and 100 mg/kg, P<0.01) and propranolol (P<0.01). In anesthetized dogs, coronary artery blood flow was increased significantly by betaglucin (30 and 100 mg/kg, P<0.01), but blood pressure, heart rate and ventricular function were not changed (P>0.05). High-dose betaglucin (100 mg/kg) increased myocardial oxygen consumption, but not to a statistically significant level (P>0.05). The hemodynamic indexes were significantly changed by propranolol.
Conclusion:
Betaglucin has protective effects on myocardial tissue during MI in rats and dogs and has no influence on hemodynamic parameters at a therapeutic dose. The increase in coronary artery blood flow induced by betaglucin might be beneficial in the treatment of patients with MI.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Kodama N, Asakawa A, Inui A, Masuda Y, Nanba H . Enhancement of cytotoxicity of NK cells by D-fraction, a polysaccharide from Grifola frondosa. Oncol Rep 2005; 13: 497–502.
Ross GD, Vetvicka V, Yan J, Xia Y, Vetvickova J . Therapeutic intervention with complement and beta-glucan in cancer. Immunopharmacology 1999; 42: 61–74.
Ho JC, Konerding MA, Gaumann A, Groth M, Liu WK . Fungal polysaccharopeptide inhibits tumor angiogenesis and tumor growth in mice. Life Sci 2004; 75: 1343–56.
LeBlanc BW, Albina JE, Reichner JS . The effect of PGG-beta-glucan on neutrophil chemotaxis in vivo. J Leukoc Biol 2006; 79: 667–75.
Kim GY, Roh SI, Park SK, Ahn SC, Oh YH, Lee JD, et al. Alleviation of experimental septic shock in mice by acidic polysaccharide isolated from the medicinal mushroom Phellinus linteus. Biol Pharm Bull 2003; 26: 1418–23.
Babineau TJ, Hackford A, Kenler A, Bistrian B, Forse RA, Fairchild PG, et al. A phase II multicenter, double-blind, randomized, placebo-controlled study of three dosages of an immunomodulator (PGG-glucan) in high-risk surgical patients. Arch Surg 1994; 129: 1204–10.
Akramiene D, Kondrotas A, Didziapetriene J, Kevelaitis E . Effects of beta-glucans on the immune system. Medicina (Kaunas) 2007; 43: 597–606.
Li C, Ha T, Kelley J, Gao X, Qiu Y, Kao RL, et al. Modulating Toll-like receptor mediated signaling by (1→3)-beta-D-glucan rapidly induces cardioprotection. Cardiovasc Res 2004; 61: 538–47.
Chihara G, Hamuro J, Maeda YY, Shiio T, Suga T, Takasuka N, et al. Antitumor and metastasis-inhibitory activities of lentinan as an immunomodulator: an overview. Cancer Detect Prev Suppl 1987; 1: 423–43.
Wasser SP . Medicinal mushrooms as a source of antitumor and immunomodulating polysaccharides. Appl Microbiol Biotechnol 2002; 60: 258–74.
Ishibashi K, Miura NN, Adachi Y, Ohno N, Yadomae T . Relationship between solubility of grifolan, a fungal 1,3-beta-D-glucan, and production of tumor necrosis factor by macrophages in vitro. Biosci Biotechnol Biochem 2001; 65: 1993–2000.
Lee DY, Ji IH, Chang HI, Kim CW . High-level TNF-alpha secretion and macrophage activity with soluble beta-glucans from Saccharomyces cerevisiae. Biosci Biotechnol Biochem 2002; 66: 233–8.
Li C, Kao RL, Ha T, Kelley J, Browder IW, Williams DL . Early activation of IKKbeta during in vivo myocardial ischemia. Am J Physiol Heart Circ Physiol 2001; 280: H1264–71.
Lin LL, Liu AJ, Liu JG, Yu XH, Qin LP, Su DF . Protective effects of scutellarin and breviscapine on brain and heart ischemia in rats. J Cardiovasc Pharmacol 2007; 50: 327–32.
Nishizawa M, Kumagai H, Ichikawa M, Oshima N, Suzuki H, Saruta T . Improvement in baroreflex function by an oral angiotensin receptor antagonist in rats with myocardial infarction. Hypertension 1997; 29: 458–63.
Leenen FH, Yuan B . Mortality after coronary artery occlusion in different models of cardiac hypertrophy in rats. Hypertension 2001; 37: 209–15.
Brown GD, Gordon S . Fungal beta-glucans and mammalian immunity. Immunity 2003; 19: 311–5.
Lee SH, Yoon SB, Cho JR, Choi S, Jung JH, Lee N . The effects of different beta-blockers on left-ventricular volume and function after primary coronary stenting in acute myocardial infarction. Angiology 2008; 59: 676–81.
Acknowledgements
The authors thank the National Science & Technology Major Project (2009ZX09303-002) and the Science and Technology Development Foundation of Shanghai (No 07JC14065) for grant support.
Author information
Authors and Affiliations
Corresponding authors
Rights and permissions
About this article
Cite this article
Qian, J., Liu, Aj., Zhang, W. et al. Protective effects of betaglucin on myocardial tissue during myocardial infarction in rats and dogs. Acta Pharmacol Sin 30, 1092–1098 (2009). https://doi.org/10.1038/aps.2009.102
Received:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/aps.2009.102
